Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

15.83
-0.2700-1.68%
Post-market: 15.43-0.4000-2.53%19:30 EDT
Volume:921.17K
Turnover:14.68M
Market Cap:874.52M
PE:-5.74
High:16.91
Open:16.32
Low:15.33
Close:16.10
52wk High:16.93
52wk Low:5.97
Shares:55.24M
Float Shares:42.02M
Volume Ratio:0.45
T/O Rate:2.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7580
EPS(LYR):-2.4200
ROE:-43.25%
ROA:-25.09%
PB:2.15
PE(LYR):-6.54

Loading ...

4D Molecular Therapeutics CEO David Kirn Disposes of Common Shares Worth $1,068,651.63

Reuters
·
Aug 22

4D Molecular Therapeutics Posts Corporate Presentation Highlighting AAV Gene Therapy Pipeline Led by 4D-150 for Wet AMD, DME

Reuters
·
Aug 21

4D Molecular Therapeutics CLO Scott Bizily Disposes of Common Shares Worth $39,567.5

Reuters
·
Aug 18

B. Riley views EyePoint study miss as positive for 4D Molecular

TIPRANKS
·
Aug 18

4D Molecular Therapeutics Grants 35,200 RSUs to Five New Hires Under Inducement Award Plan

Reuters
·
Aug 15

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)

TIPRANKS
·
Aug 14

Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Aug 14

Cantor Fitzgerald Reaffirms Their Hold Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Aug 14

Analyst Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target as 4D-150 Advances Through Late-Stage Trials

TIPRANKS
·
Aug 14

4D Molecular Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

4D Molecular Therapeutics Q2 Net Loss Widens

Reuters
·
Aug 14

4D Molecular Therapeutics Q2 EPS $(1.04) Beats $(1.06) Estimate, Sales $3.781M Beat $3.100M Estimate

Benzinga Earnings
·
Aug 14

4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million

Reuters
·
Aug 14

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

GlobeNewswire
·
Aug 14

4D Molecular Therapeutics Inc Expected to Post a Loss of $1.02 a Share - Earnings Preview

Reuters
·
Aug 07

4D Molecular Therapeutics CEO David Kirn Disposes of 12,415 Shares Worth $124,987

Reuters
·
Aug 05

4D Molecular Therapeutics Inc : B. Riley Initiates Coverage with Buy Rating; Target Price $37

THOMSON REUTERS
·
Jul 31

B. Riley Initiates 4D Molecular Therapeutics at Buy With $37 Price Target

MT Newswires Live
·
Jul 31

U.S. Research ROUNDUP-Apple, Amazon, Mastercard

Reuters
·
Jul 31

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tempus AI, Inc. Class A (TEM) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Jul 21